GUNTHER TULIP VENA CAVA FILTER

K072240 · Cook, Inc. · DTK · Nov 8, 2007 · Cardiovascular

Device Facts

Record IDK072240
Device NameGUNTHER TULIP VENA CAVA FILTER
ApplicantCook, Inc.
Product CodeDTK · Cardiovascular
Decision DateNov 8, 2007
DecisionSESE
Submission TypeSpecial
Regulation21 CFR 870.3375
Device ClassClass 2
AttributesTherapeutic

Intended Use

The proposed Günther Tulip™ Vena Cava Filter is intended for the prevention of recurrent pulmonary embolism via placement in the vena cava in the following situations: Pulmonary thromboembolism when anticoagulant therapy is contraindicated; Failure of anticoagulant therapy in thromboembolic diseases; Emergency treatment following massive pulmonary embolism where anticipated benefits of conventional therapy are reduced; and chronic, recurrent pulmonary embolism where anticoagulant therapy has failed or is contraindicated. The Günther Tulip™ Vena Cava Filter may be retrieved according to the instructions supplied in the section labeled: Optional Retrieval Procedure. The Günther Tulip™ Vena Cava Filter Retrieval Filter Set has been designed for retrieval of an implanted Günther Tulip™ Vena Cava Filter in patients who no longer require a filter. Retrieval of the filter can be performed only by the jugular approach.

Device Story

Intravascular filter designed for placement in vena cava to prevent pulmonary embolism; conical design with four legs. Available in femoral, jugular, or universal sets. Introduced via 8.5 French coaxial sheath system; includes pre-loaded filter, introducer, hydrophilic coated dilator, and three-way stopcock. Used by physicians in clinical settings. Optional retrieval set allows removal of filter via jugular approach for patients no longer requiring therapy. Device is sterile, single-use. Benefits include mechanical prevention of thromboembolism in patients where anticoagulation is not viable.

Clinical Evidence

Bench testing only. Testing included tensile, flow rate, static burst, three-point bend, drop, biocompatibility, and accelerated aging tests to ensure design and performance conformance.

Technological Characteristics

Conical, four-leg filter design. 8.5 French coaxial introducer sheath system. 71 cm long power-injectable dilator. Hydrophilic coating. Sterile, single-use. Mechanical device; no software or energy source.

Indications for Use

Indicated for patients requiring prevention of recurrent pulmonary embolism due to contraindication or failure of anticoagulant therapy, or following massive pulmonary embolism where conventional therapy benefits are reduced. Includes optional retrieval for patients no longer requiring the filter.

Regulatory Classification

Identification

A cardiovascular intravascular filter is an implant that is placed in the inferior vena cava for the purpose of preventing pulmonary thromboemboli (blood clots generated in the lower limbs and broken loose into the blood stream) from flowing into the right side of the heart and the pulmonary circulation.

Special Controls

*Classification.* Class II. The special controls for this device are:(1) “Use of International Standards Organization's ISO 10993 ‘Biological Evaluation of Medical Devices Part I: Evaluation and Testing,’ ” and (2) FDA's: (i) “510(k) Sterility Review Guidance and Revision of 2/12/90 (K90-1)” and (ii) “Guidance for Cardiovascular Intravascular Filter 510(k) Submissions.”

Predicate Devices

Related Devices

Submission Summary (Full Text)

{0}------------------------------------------------ K072240 p. 1 of 2 95 Special 510(k): Device Modification Günther Tulip™ Vena Cava Filter COOK INCORPORATED 9 August 2007 #### 510(k) SUMMARY Submitted By: Molly Busenbark Cook Incorporated 750 Daniels Way, P.O. Box 489 Bloomington, IN (812) 339-2235 x 2162 NOV 0 8 2007 ### Device: | Trade Name: | Günther Tulip™ Vena Cava Filter | |--------------------------|-------------------------------------| | Proposed Classification: | Cardiovascular Intravascular Filter | ### Indications for Use: The proposed Günther Tulip Vena Cava Filter is intended for the prevention of recurrent pulmonary embolism via placement in the vena cava in the following situations: - Pulmonary thromboembolism when anticoagulant therapy is . contraindicated; - Failure of anticoagulant therapy in thromboembolic diseases; ● - Emergency treatment following massive pulmonary embolism where . anticipated benefits of conventional therapy are reduced; and - chronic, recurrent pulmonary embolism where anticoagulant therapy has failed or is contraindicated. The Günther Tulip™ Vena Cava Filter may be retrieved according to the instructions supplied in the section labeled: Optional Retrieval Procedure. ## Retrieval Set The Günther Tulip™ Vena Cava Filter Retrieval Filter Set has been designed for retrieval of an implanted Günther Tulip™ Vena Cava Filter in patients who no longer require a filter. Retrieval of the filter can be performed only by the jugular approach. ### Predicate Device: The Günther Tulip™ Vena Cava Filter is similar in terms of intended use, materials of construction, and technological characteristics to the predicate Günther Tulip "Vena Cava Filter. ## Device Description: The Günther Tulip 10 Vena Cava Filter is available in femoral version, jugular version, or a universal set. The femoral set is introduced through the femoral vein, while the jugular {1}------------------------------------------------ Special 510(k): Device Modification Günther Tulip™ Vena Cava Filter COOK INCORPORATED 9 August 2007 set is introduced through the jugular vein. The universal set includes both femoral and jugular vein versions. The device consists of a pre-loaded filter introducer, a coaxial introducer sheath system, a hydrophilic coated dilator, and a three-way stopcock. The filter is introduced and placed via an 8.5 French coaxial introducer sheath system. The introducer dilator is an 8.5 French power injectable dilator that is 71 centimeters long. The basic design of the filter is conical with four legs. The filter is supplied sterile in peel-open packages and intended for one-time use. # Substantial Equivalence: Cook Incorporated currently markets the predicate Günther Tulip™ Vena Cava Filter, which is substantially equivalent to the Günther Tulip™ Vena Cava Filter subject of this submission. The similar indications for use and technological characteristics of the Günther Tulip™ Vena Cava Filter as compared to the predicate device support a determination of substantial equivalence. # Test Data: The proposed Günther Tulip™ Vena Cava Filter was subjected to the following tests to assure reliable design and performance under the specified testing parameters. - Tensile Testing 제 - I Flow Rate Testing - Static Burst Testing - 트 Three-Point Bend Testing - Drop Testing - Biocompatibility Testing - 체 Accelerated Aging Testing The results of these tests provide reasonable assurance that the device has been designed and tested to assure conformance to the requirements for its intended use. {2}------------------------------------------------ Image /page/2/Picture/2 description: The image shows the seal of the Department of Health and Human Services (HHS). The seal features the department's name encircling a stylized caduceus symbol. The caduceus is represented by a staff with three intertwined snakes, symbolizing medicine and health. The text around the symbol reads "DEPARTMENT OF HEALTH AND HUMAN SERVICES. USA". Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 NOV 0 8 2007 Cook Incorporated c/o Ms. Molly Busenbark Regulatory Affairs Specialist P.O. Box 489 Bloomington, IN 47402 Re: K072240 Günther Tulip™ Vena Cava Filter Regulation Number: 21 CFR 870.3375 Regulation Name: Cardiovascular intravascular filter Regulatory Class: Class II (two) Product Code: DTK Dated: October 4, 2007 Received: October 9, 2007 Dear Ms. Busenbark: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {3}------------------------------------------------ Page 2 - Ms. Molly Busenbark Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97) you may obtain. Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html Sincerely yours, R. lochner Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ #### Indications for Use | 510(k) Number (if known): | K072240 | |---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Device Name: | Günther Tulip <sup>TM</sup> Vena Cava Filter | | Indications for Use: | The proposed Günther Tulip <sup>TM</sup> Vena Cava Filter is<br>intended for the prevention of recurrent pulmonary<br>embolism via placement in the vena cava in the following<br>situations: | | | • Pulmonary thromboembolism when anticoagulant therapy is | - contraindicated: - Failure of anticoagulant therapy in thromboembolic diseases; . - Emergency treatment following massive pulmonary embolism where . anticipated benefits of conventional therapy are reduced; and - chronic, recurrent pulmonary embolism where anticoagulant therapy has . failed or is contraindicated. The Günther Tulip™ Vena Cava Filter may be retrieved according to the instructions supplied in the section labeled: Optional Retrieval Procedure. Retrieval Set The Günther Tulip™ Vena Caya Filter Retrieval Filter Set has been designed for retrieval of an implanted Günther Tulip™ Vena Cava Filter in patients who no longer require a filter. Retrieval of the filter can be performed only by the jugular approach. Prescription Use XX (Part 21 CFR 801 Subpart D) OR Over-the-Counter Use (21 CFR 801 Subpart C) # (PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) (Division Sign-Off) Division of Cardiovascular Devices 510(k) Number_Ko22240
Innolitics

Panel 1

/
Sort by
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...